HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates.

Abstract
The level of maternal circulating triacylglycerols during late pregnancy has been correlated with the mass of newborns. PPARgamma (peroxisome-proliferator-activated receptor gamma) ligands, such as TZDs (thiazolidinediones), have been shown to reduce triacylglycerolaemia and have also been implicated in the inhibition of tissue growth and the promotion of cell differentiation. Therefore TZDs might control cell proliferation during late fetal development and, by extension, body mass of pups. To investigate the response to EZ (englitazone), a TZD, on perinatal development, 0 or 50 mg of englitazone/kg of body mass was given as an oral dose to pregnant rats daily from day 16 of gestation until either day 20 for the study of their fetuses, or until day 21 of gestation for the study of neonates. EZ decreased maternal triacylglycerol levels at day 20 of gestation and neonatal mass, but not fetal mass. Fetuses and neonates from EZ-treated mothers exhibited high levels of insulin and were found to be hyperglycaemic. The apparent insulin-resistant state in neonates from EZ-treated pregnant rats was corroborated, since they showed higher plasma NEFA [non-esterified ('free') fatty acid] levels, ketonaemia and liver LPL (lipoprotein lipase) activity and lower plasma IGF-I (type 1 insulin-like growth factor) levels, in comparison with those from control mothers. Moreover, at the molecular level, an increase in Akt phosphorylation was found in the liver of neonates from EZ-treated mothers, which confirms that the insulin pathway was negatively affected. Thus the response of fetuses and neonates to maternal antidiabetic drug treatment is the opposite of what would be expected, and can be justified by the scarce amount of adipose tissue impeding a normal response to PPARgamma ligands and by hyperinsulinaemia as being responsible for a major insulin-resistant condition.
AuthorsJulio Sevillano, Inmaculada C López-Pérez, Emilio Herrera, María Del Pilar Ramos, Carlos Bocos
JournalThe Biochemical journal (Biochem J) Vol. 389 Issue Pt 3 Pg. 913-8 (Aug 01 2005) ISSN: 1470-8728 [Electronic] England
PMID15810879 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzopyrans
  • Fatty Acids, Nonesterified
  • Hypolipidemic Agents
  • Insulin
  • Ketones
  • Thiazolidinediones
  • Triglycerides
  • Insulin-Like Growth Factor I
  • Lipoprotein Lipase
  • englitazone
Topics
  • Animals
  • Animals, Newborn
  • Benzopyrans (toxicity)
  • Body Weight (drug effects)
  • Fatty Acids, Nonesterified (blood)
  • Female
  • Fetal Development (drug effects)
  • Hypolipidemic Agents (toxicity)
  • Insulin (blood)
  • Insulin Resistance
  • Insulin-Like Growth Factor I
  • Ketones (blood)
  • Lipoprotein Lipase (metabolism)
  • Liver (enzymology)
  • Pregnancy
  • Prenatal Exposure Delayed Effects
  • Rats
  • Rats, Sprague-Dawley
  • Thiazolidinediones (toxicity)
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: